Indian Drugmaker’s Products Banned From U.S. Market After Drug Shortage Ends

Drug Industry Daily
The FDA has broadened its import ban against Indian manufacturer Ipca Laboratories to include four drugs previously exempted due to shortage. Only Ipca’s anti-malarial API remains exempted and can be imported into the U.S.

To View This Article:


Subscribe To Drug Industry Daily